Onset of effects of testosterone treatment and time span until maximum effects are achieved
Reads0
Chats0
TLDR
The time-course of the spectrum of effects of testosterone shows considerable variation, probably related to pharmacodynamics of the testosterone preparation, androgen receptor polymorphism and intracellular steroid metabolism further contribute to such diversity.Abstract:
Objective: Testosterone has a spectrum of effects on the male organism. This review attempts to determine, from published studies, the time-course of the effects induced by testosterone replacement therapy from their first manifestation until maximum effects are attained. Design: Literature data on testosterone replacement. Results: Effects on sexual interest appear after 3 weeks plateauing at 6 weeks, with no further increments expected beyond. Changes in erections/ejaculations may require up to 6 months. Effects on quality of life manifest within 3‐4 weeks, but maximum benefits take longer. Effects on depressive mood become detectable after 3‐6 weeks with a maximum after 18‐30 weeks. Effects on erythropoiesis are evident at 3 months, peaking at 9‐12 months. Prostate-specific antigen and volume rise, marginally, plateauing at 12 months; further increase should be related to aging rather than therapy. Effects on lipids appear after 4 weeks, maximal after 6‐12 months. Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3‐12 months. Changes in fat mass, lean body mass, and muscle strength occur within 12‐16 weeks, stabilize at 6‐12 months, but can marginally continue over years. Effects on inflammation occur within 3‐12 weeks. Effects on bone are detectable already after 6 months while continuing at least for 3 years. Conclusion: The time-course of the spectrum of effects of testosterone shows considerable variation, probably related to pharmacodynamics of the testosterone preparation. Genomic and non-genomic effects, androgen receptor polymorphism and intracellular steroid metabolism further contribute to such diversity.read more
Citations
More filters
Journal ArticleDOI
Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis
Giovanni Corona,Giulia Rastrelli,Matteo Monami,Farid Saad,Michaela Luconi,Marcello Lucchese,Enrico Facchiano,Alessandra Sforza,Gianni Forti,Edoardo Mannucci,Mario Maggi +10 more
TL;DR: Weight loss is associated with an increase in both bound and unbound testosterone levels, and the normalization of sex hormones induced by body weight loss is a possible mechanism contributing to the beneficial effects of surgery in morbid obesity.
Journal ArticleDOI
Testosterone and obesity.
TL;DR: Testosterone replacement therapy demonstrates beneficial effects on measures of obesity that are partially explained by both direct metabolic actions on adipose and muscle and also potentially by increasing motivation, vigour and energy allowing obese individuals to engage in more active lifestyles.
Journal ArticleDOI
Testosterone Deficiency in Men: Systematic Review and Standard Operating Procedures for Diagnosis and Treatment
TL;DR: A standardized process for diagnosis and treatment of Testosterone (T) deficiency is proposed, and the knowledge on T therapy (Tth) and prostate and cardiovascular safety is updated.
Journal ArticleDOI
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men
Bruno Lunenfeld,George Mskhalaya,Michael Zitzmann,Stefan Arver,Svetlana Kalinchenko,Yuliya Tishova,Abraham Morgentaler +6 more
TL;DR: Recommendations on the clinical spectrum of hypogonadism related to metabolic and idiopathic disorders that contribute to the majority of cases that occur in adult men are focused on.
Journal ArticleDOI
A Critical Analysis of the Role of Testosterone in Erectile Function: From Pathophysiology to Treatment—A Systematic Review
Andrea M. Isidori,Jacques Buvat,Giovanni Corona,Irwin Goldstein,Emmanule A. Jannini,Andrea Lenzi,Hartmut Porst,Andrea Salonia,Abdulmaged M. Traish,Mario Maggi +9 more
TL;DR: A body of molecular and clinical evidence supports the use of TRT in hypogonadal patients with ED, although the benefit-risk ratio is uncertain in advanced age, and an improved diagnosis and individualized management is desirable.
References
More filters
Journal ArticleDOI
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.
Shalender Bhasin,Glenn R. Cunningham,Frances J. Hayes,Alvin M. Matsumoto,Peter J. Snyder,Ronald S. Swerdloff,Victor M. Montori +6 more
TL;DR: The guidelines for the evaluation and treatment of androgen deficiency syndromes in adult men published previously in 2006 were updated by the Task Force of the Clinical Guidelines Subcommittee of The Endocrine Society.
A Systematic Review and Meta-Analysis of Randomized Controlled Trials
TL;DR: The current evidence does not support the routine use of cryotherapy after total knee arthroplasty, and the patient-centered outcomes remain underinvestigated.
Journal ArticleDOI
Adverse Events Associated with Testosterone Administration
Shehzad Basaria,Andrea D. Coviello,Thomas G. Travison,Thomas W. Storer,Wildon Farwell,Wildon Farwell,Alan M. Jette,Richard Eder,Sharon L. Tennstedt,Jagadish Ulloor,Anqi Zhang,Karen Choong,Kishore M. Lakshman,Norman A. Mazer,Renee Miciek,Joanne B. Krasnoff,Ayan Elmi,Philip E. Knapp,Brad Brooks,Erica R. Appleman,Sheetal Aggarwal,Geeta Bhasin,Leif Hede-Brierley,Ashmeet Bhatia,Lauren Collins,Nathan K. LeBrasseur,Louis D. Fiore,Shalender Bhasin +27 more
TL;DR: In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events.
Journal ArticleDOI
Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations
Cong-Yi Wang,Eberhard Nieschlag,Ronald S. Swerdloff,Hermann M. Behre,Wayne Jg Hellstrom,Louis Gooren,Jean-Marc Kaufman,Jean-Jacques Legros,Bruno Lunenfeld,Alvaro Morales,John E. Morley,Claude Schulman,Ian M. Thompson,Wolfgang Weidner,Frederick C. W. Wu +14 more
TL;DR: In this paper, the effects of androgen treatment of hypogonadal men on multiple target organs and the recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men.
Journal ArticleDOI
Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men
Christina Wang,Ronald S. Swerdloff,Ali Iranmanesh,Adrian S. Dobs,Peter J. Snyder,Glenn R. Cunningham,Alvin M. Matsumoto,Thomas Weber,Nancy Berman +8 more
TL;DR: It is concluded that T gel replacement improved sexual function and mood, increased lean mass and muscle strength (principally in the legs), and decreased fat mass in hypogonadal men with less skin irritation and discontinuation compared with the recommended dose of the permeation-enhanced T patch.
Related Papers (5)
Identification of late-onset hypogonadism in middle-aged and elderly men.
Frederick C. W. Wu,Abdelouahid Tajar,Jennifer M. Beynon,Stephen R Pye,Alan J. Silman,Joseph D. Finn,Terence W O'Neill,Gyorgy Bartfai,Felipe F. Casanueva,Gianni Forti,Aleksander Giwercman,Thang S. Han,Krzysztof Kula,Michael E. J. Lean,Neil Pendleton,Margus Punab,Steven Boonen,Dirk Vanderschueren,Fernand Labrie,Ilpo Huhtaniemi +19 more
Adverse Events Associated with Testosterone Administration
Shehzad Basaria,Andrea D. Coviello,Thomas G. Travison,Thomas W. Storer,Wildon Farwell,Wildon Farwell,Alan M. Jette,Richard Eder,Sharon L. Tennstedt,Jagadish Ulloor,Anqi Zhang,Karen Choong,Kishore M. Lakshman,Norman A. Mazer,Renee Miciek,Joanne B. Krasnoff,Ayan Elmi,Philip E. Knapp,Brad Brooks,Erica R. Appleman,Sheetal Aggarwal,Geeta Bhasin,Leif Hede-Brierley,Ashmeet Bhatia,Lauren Collins,Nathan K. LeBrasseur,Louis D. Fiore,Shalender Bhasin +27 more